Flare Therapeutics Inks Pact with Roche to Develop Small Molecules Targeting Undrugged Transcription Factors in Oncology
Shots:
- The alliance will discover small molecule therapeutics targeting undrugged transcription factors in oncology, using Flare’s proteomic & mass spectrometry platform as well as electrophilic compounds library
- Flare will lead discovery & preclinical work plus is entitled to get $70M upfront in cash, >$1.8B discovery, development & commercialization milestones along with royalties, while Roche will handle further development & commercialization
- Flare keeps the right to co-fund the development of one target in exchange for higher US royalties. It also retains ownership of its pipeline, incl. FX-909 for advanced urothelial cancer (entering IND-enabling trials) as well as other oncology & therapeutic programs
Ref: Flare Therapeutics | Image: Roche & Flare Therapeutics
Related News:- Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
flare therapeutics
roche
small molecules
oncology
biotech
alliance
small molecule therapeutics
flare
proteomics
mass spectrometry
electrophilic compounds library
discovery and preclinical work
co-funding development
higher us royalties
fx-909
advanced urothelial cancer
ind-enabling trials
pipeline
therapeutic programs has context menu
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
